drugset / Trial / NCT00240695

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

NCT00240695

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine

Timeline

Start
2003-05
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 8 mg Oral
Subject Galantamine Small molecule 12 mg Oral